3
Registered trials
1
Recruiting
2
Unique sponsors
6
Unique IMPs
3
Commercial trials
Drug classes (ATC)
L
Oncology (ATC L)
2
—
ATC code not specified
1
Mechanism of action (INN-stem analysis)
Kinase inhibitor
3 substances
Unknown / small molecule
2 substances
Checkpoint inhibitor (PD-1)
1 substance
Phase III:
1
Phase I (First in Human):
2
Phase III
1 trial-
EndedAstraZeneca AB CommercialSAVOLITINIB; SUNITINIB
Phase I (First in Human)
2 trials-
EndedSalubris Biotherapeutics Inc. CommercialJK08; LENVATINIB; PEMBROLIZUMAB
-
RecruitingSalubris Biotherapeutics Inc. CommercialJK06
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Salubris Biotherapeutics Inc. | Commercial | 2 | Phase I (First in Human) | 1 |
| AstraZeneca AB | Commercial | 1 | Phase III | 0 |
New trials by year
2021
1
2022
1
2025
1